Sales Growth YoY (Last Twelve Months): Galecto Corporation (GLTO)

Graphic logo of Galecto Corporation (GLTO)

Galecto, Inc. (GLTO) aims for dominance in fibrosis treatment through its unique selective inhibitors. The 12-month year-over-year revenue growth rate illustrates the path toward this goal, where the value of 0.00 determines the metric's magnitude. However, monetization via royalties and the restructuring of the R&D pipeline following failed tests remain significant challenges for the company's current business dynamics.

Sales Growth YoY (Last Twelve Months): Galecto Corp (GLTO) for 02/11/2024 - 03/10/2026

galecto.com (GLTO) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price Galecto Corporation|GLTO - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Galecto, Inc.|GLTO - Enterprise Value
- business book valuation details:
Net Assets per Share Galecto|GLTO - Company Book Value|Market Capitalization to Book Value galecto.com|GLTO - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio Galecto, Inc.|GLTO - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Galecto|GLTO - Company Aggregate Debts|Debts to Book Capitalization Galecto Inc|GLTO - Company Long-Term Debt|Company Short-Term Debt Galecto|Immediate Liquidity galecto.com
- company profitability and valuation multiples indicators:
GLTO - Net Profit|Future Profit Galecto, Inc.|GLTO - Price to Earnings Ratio|Market Cap to Future Earnings Ratio galecto.com|GLTO - Price/Earnings to Growth Ratio|Company Value to EBITDA Galecto Corp|GLTO - Operating profit before deduction of amortization|Earnings per share for the trailing year Galecto|GLTO - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months galecto.com|GLTO - Earnings per share growth in current year|Projected earnings per share growth rate for next year Galecto, Inc.
- sales and revenue data:
GLTO - Revenue and Sales Volume|Company Future Sales Volume Galecto, Inc.|GLTO - Market Cap to Revenue|Market Cap to Expected Sales Ratio Galecto, Inc.|GLTO - Sales Growth YoY (TTM)
Summary company analytics:GLTO (Galecto Corporation)
Mass-produced product of Galecto, Inc.

Investors are assessing the potential of Galecto, Inc. (GLTO) through revenue dynamics, where the trailing twelve months (TTM) sales growth measures the pace of business expansion relative to the previous year. When analyzing this LTM sales growth chart on the GURU.Markets platform, it is important to note that the flexible delegation of trials to external CRO contractors allows Galecto, Inc. (GLTO) to optimize its budget, directly influencing the final trajectory of this indicator.

Competitors of Galecto, Inc. (GLTO)

Ascendis (ASND) - Trailing Twelve Months Revenue Growth|MDGL - Sales Growth YoY (Last Twelve Months)|CORT: Sales Growth YoY (Last Twelve Months)|RYTM: Sales Growth YoY (TTM)|AKRO - Annual Revenue Growth (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) Metsera Therapeutics|MoonLake Corp (MLTX) - Annual Revenue Growth (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) crinetics.com (CRNX)|Revenue Growth YoY (Last 12 Months) newamsterdampharma.com NAMS|Sales Growth YoY (Last Twelve Months) Soleno Therapeutics Inc SLNO|Sales Growth YoY (TTM) Amicus Therapeutics Inc FOLD|89bio Corp - Sales Growth YoY (TTM)|Revenue Growth Rate YoY (Last Twelve Months) Agios Pharmaceuticals Inc (AGIO)|Structure Therapeutics (GPCR) - Sales Growth YoY (Last Twelve Months)|Revenue Growth YoY (Last 12 Months) MiMedx Group, Inc.|Sales Growth YoY (Last Twelve Months) Rezolute Bio|Lexicon Pharmaceuticals, Inc. (LXRX) - Annual Revenue Growth (Last Twelve Months)|Sales Growth YoY (TTM) MBX|Revenue Growth YoY (Last 12 Months) Altimmune, Inc. ALT|Sales Growth YoY (TTM) AARD (Aardvark Pharma)|Sagimet Biosciences Inc. (SGMT) - Trailing Twelve Months Revenue Growth|BIOA: Revenue Growth YoY (Last 12 Months)|Revenue Dynamics YoY (Last Twelve Months) BMEA (Biomea Fusion)|QNCX (quincetx.com) - Revenue Growth YoY (Last 12 Months)|Fractyl - Revenue Dynamics YoY (Last Twelve Months)|VTVT (vTv Therapeutics Inc) - Sales Growth YoY (TTM)|Agape ATP - Trailing Twelve Months Sales Growth|Revenue Growth YoY (Last 12 Months) PLUR (Pluri Inc)|Annual Revenue Growth (Last Twelve Months) Synlogic Inc.|Sales Growth YoY (Last Twelve Months) Lipocine Inc. LPCN|Matinas BioPharma (MTNB) - Trailing Twelve Months Revenue Growth|Spruce Biosciences Inc. - Sales Growth YoY (TTM)|Trailing Twelve Months Sales Growth CTCX|LUMO (Lumos Pharma) - Revenue Growth YoY (Last 12 Months)|Sales Growth YoY (Last 12 Months) ONVO|RDUS (Radius Pharmaceuticals) - Sales Growth YoY (TTM)